Indications for INJECTAFER:
Iron deficiency anemia in adults who have intolerance or insufficient response to oral iron; or have non-dialysis-dependent chronic kidney disease.
Give by slow IV push (undiluted) at rate of approx. 100mg (2mL)/min; or by IV infusion (diluted) administered over at least 15 mins. When giving via IV infusion, dilute to concentration not less than 2mg iron/mL. Give in 2 doses separated by >7 days. <50kg: 15mg/kg/dose. ≥50kg: 750mg/dose. Total cumulative dose per course: max 1500mg. May repeat treatment if condition reoccurs.
Monitor for hypersensitivity reactions during and after administration for ≥30mins and until clinically stable. Have epinephrine inj immediately available. Possible risk for hypophosphatemia if history of GI disorders associated with malabsorption of fat-soluble vitamins or phosphate, hyperparathyroidism, vitamin D deficiency, malnutrition. Monitor serum phosphate levels in at-risk patients who require a repeat course. Monitor for hypertension after each administration. Avoid extravasation. Neonates. Pregnancy. Nursing mothers: monitor infants for GI toxicity.
Possible risk for hypophosphatemia with concurrent or prior use of drugs that affect proximal renal tubular function. Lab assays may overestimate serum iron and transferrin bound iron within 24hrs after administration.
Nausea, hypertension, flushing, hypophosphatemia, dizziness; rare: hypersensitivity reactions.
Generic Drug Availability:
Single-dose vial (15mL)—1, 2